Imidex Hires Wes Bolsen as CEO to Commercialize FDA-Cleared Artificial Intelligence Device for Lung Nodule and Mass Detection, Indicative of Potential Early-Stage Lung Cancer
Company is evaluating strategic partners and potential acquirers who could potentially treat 50% more lung nodule patients in the U.S. and save billions of dollars annually in healthcare costs.
